Feasibility of using contrast-free quantitative magnetic resonance imaging for liver sparing stereotactic ablative body radiotherapy.

Biologically-guided radiotherapy Functional MR Liver cancer Liver sparing Quantitative imaging SABR

Journal

Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416

Informations de publication

Date de publication:
Nov 2024
Historique:
received: 15 07 2024
revised: 06 09 2024
accepted: 10 09 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 8 10 2024
Statut: epublish

Résumé

Tumours in the liver often develop on a background of liver cirrhosis and impaired liver function. As a result, radiotherapy treatments are limited by radiation-induced liver disease, parameterised by the liver mean dose (LMD). Liver function is highly heterogeneous, especially in liver cancer, but the use of LMD does not take this into account. One possible way to improve liver treatments is to use quantitative imaging techniques to assess liver health and prioritise the sparing of healthy liver tissue. Anatomical T2 and quantitative iron-corrected T1 (cT1) images were made available for 10 patients with liver metastases. Functional liver volumes were automatically segmented on the quantitative images using a threshold. Liver stereotactic ablative body radiotherapy (SABR) plans were made using a departmental protocol. Liver-sparing plans were then made by reducing the dose to the functional sub-volume. The sparing plans achieved a statistically significant ( This study has, for the first time, demonstrated the use of cT1 maps in radiotherapy showing significant reductions in dose to the healthy liver. Further work is needed to validate this in liver cancer patients, who would likely benefit most.

Sections du résumé

Background and purpose UNASSIGNED
Tumours in the liver often develop on a background of liver cirrhosis and impaired liver function. As a result, radiotherapy treatments are limited by radiation-induced liver disease, parameterised by the liver mean dose (LMD). Liver function is highly heterogeneous, especially in liver cancer, but the use of LMD does not take this into account. One possible way to improve liver treatments is to use quantitative imaging techniques to assess liver health and prioritise the sparing of healthy liver tissue.
Materials and methods UNASSIGNED
Anatomical T2 and quantitative iron-corrected T1 (cT1) images were made available for 10 patients with liver metastases. Functional liver volumes were automatically segmented on the quantitative images using a threshold. Liver stereotactic ablative body radiotherapy (SABR) plans were made using a departmental protocol. Liver-sparing plans were then made by reducing the dose to the functional sub-volume.
Results UNASSIGNED
The sparing plans achieved a statistically significant (
Conclusions UNASSIGNED
This study has, for the first time, demonstrated the use of cT1 maps in radiotherapy showing significant reductions in dose to the healthy liver. Further work is needed to validate this in liver cancer patients, who would likely benefit most.

Identifiants

pubmed: 39376618
doi: 10.1016/j.ctro.2024.100859
pii: S2405-6308(24)00136-8
pmc: PMC11456905
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100859

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Frank Brewster (F)

Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK.

Zoe Middleton (Z)

Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Alan McWilliam (A)

Department of Radiotherapy Related Research, Division of Clinical Cancer Science, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK.

Andrew Brocklehurst (A)

Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

Ganesh Radhakrishna (G)

Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

Robert Chuter (R)

Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK.
Department of Radiotherapy Related Research, Division of Clinical Cancer Science, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK.

Classifications MeSH